Checkmate Pharmaceuticals is conducting a study of vidutolimod (CMP-001) in combination with pembrolizumab for the first-line treatment of metastatic or unresectable head and neck squamous cell carcinoma (HNSCC). HNSCC represents a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth. According to the National Institutes for Health, HNSCC is the seventh most common cancer worldwide. Approximately 600,000 new cases are diagnosed each year, including about 50,000 in the United States. HNSCC is more than twice as prevalent among men. Treatments for HNSCC can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments including immunotherapy.


CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Identifier: NCT04633278
A Phase 2 study of vidutolimod intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed cell death protein 1 (PD-1) blocking antibody.

Clinical Trial Overview

The primary objective of the study is to determine the Investigator-assessed confirmed objective response with vidutolimod in combination with pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC).

To learn more about this clinical trial or to view a list of recruiting trial sites, please visit:

Vidutolimod is an investigational immunotherapy being evaluated in clinical studies and has not been approved by the FDA or any other agency. Clinical trials are designed to evaluate the safety and efficacy of investigational therapies. Please consult your doctor about your eligibility and the benefits and risks of participating in our trials.